Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 6/20 | 0.34 |
| ▸ | METAP1 | P53582 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20756140 | 1.00 | KMT2A (0.35) | KMT2ATDP1MEN1METAP2METAP1 | |
| SCHEMBL22503373 | 1.00 | KMT2A (0.35) | KMT2ATDP1MEN1METAP2METAP1 | |
| SCHEMBL19590206 | 1.00 | KMT2A (0.35) | KMT2ATDP1MEN1METAP2METAP1 | |
| SCHEMBL19993754 | 0.86 | — | — | |
| SCHEMBL25525341 | 0.86 | — | — | |
| SCHEMBL805116 | 0.82 | MGAM (0.44) | METAP2METAP1ALDH1A1HPGD | |
| SCHEMBL10204950 | 0.82 | MGAM (0.44) | METAP2METAP1ALDH1A1HPGD | |
| SCHEMBL4680662 | 0.82 | MGAM (0.44) | METAP2METAP1ALDH1A1HPGD | |
| SCHEMBL5676869 | 0.81 | METAP2 (0.36) | KMT2AMETAP2METAP1POLB | |
| SCHEMBL5676873 | 0.81 | METAP2 (0.36) | KMT2AMETAP2METAP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472826-B2 | Acyclic antivirals | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-18 | — | — | US | disclosed |
| US-20200392169-A1 | ACYCLIC ANTIVIRALS | JANSSEN BIOPHARMA, LLC | 2020-12-17 | — | — | US | disclosed |
| US-10370401-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472826-B2 | Acyclic antivirals | PNP, DUT, TYMP | KMT2A 2535/4885TDP1 281/4885MEN1 3250/4885 |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | KMT2A 3315/4885TDP1 367/4885MEN1 3891/4885 |
| US-20200392169-A1 | ACYCLIC ANTIVIRALS | PNP, DUT, TYMP | KMT2A 2535/4885TDP1 281/4885MEN1 3250/4885 |
| US-10370401-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, NUDT1 | KMT2A 3315/4885TDP1 367/4885MEN1 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.